Jul. 28, 2015, 3:42 AM
- Hikma Pharmaceuticals (OTCPK:HKMPY) will buy Boehringer Ingelheim GmbH’s Roxane business for $2.65B to become the sixth-largest supplier of generic medicines in the U.S.
- Hikma, which will pay $1.18B in cash and issue 40M new shares to Boehringer, has also agreed to make milestone cash payments of up to $125M.
Jun. 30, 2015, 10:08 AM| Jun. 30, 2015, 10:08 AM | 3 Comments
May 28, 2014, 8:27 AM
- Hikma Pharmaceuticals (HKMPF) has agreed to buy the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300M, as it attempts to boost its "injected medicine" market share.
- The company will pay $225M upfront for the assets of Boehringer's Bedford Laboratories and another $75M over the course of five years based on the performance of the drugs.
Nov. 23, 2011, 1:59 PM